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OBJECTIVE: Mortality and economic consequences associated
with Candida bloodstream infections are considerable, and the
incidence of Candida glabrata infections is increasing. This
investigation aimed to evaluate inpatient costs, length of stay
(LOS), and mortality associated with candidemia in adults 18
years, focusing on differences between Candida glabrata and
Candida albicans. METHODS: The study cohort consisted of all
patients hospitalized at Duke University Medical Center from
February 1996 to July 2007 with a blood culture positive for
C. glabrata or C. albicans. Patients were stratiﬁed according to
whether their ﬁrst positive culture occurred within the ﬁrst two
days of hospital admission or thereafter. Detailed cost account-
ing data were available since December 2002. Generalized linear
models using gamma distributions and log links were used to
compare costs, negative binomial models for LOS, and chi-
square tests for inpatient mortality. RESULTS: A total of 241
adults with C. glabrata and 402 adults with C. albicans blood-
stream infections were identiﬁed. Complete data on LOS was
available for 99.1% and cost data for 38.1%. Approximately
20% of patients had a positive blood culture within the ﬁrst two
days of admission (C. glabrata, 18.7%; C. albicans, 21.1%).
Among these patients, those with C. glabrata versus C. albicans
had longer LOS (19.7 days vs. 14.2 days, p = 0.03), higher costs
($56,026 vs. $31,168, p = 0.02), and comparable mortality rates
(33.3% vs. 35.3%, p = 0.82). Among patients in whom the ﬁrst
positive blood culture occurred later, LOS (22.0 days vs. 20.1
days, p = 0.29), costs ($68,280 vs. $51,688, p = 0.06) and inpa-
tient mortality (48.5% vs. 44.8%, p = 0.42) were more similar.
CONCLUSION: Candida bloodstream infections in adult
patients are associated with substantial costs, long LOS, and
high mortality rates. Unadjusted comparisons revealed longer
inpatient stays and higher costs among patients with early
evidence of bloodstream infection with C. glabrata relative to
C. albicans.
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FUNCTION (CHIEF)
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OBJECTIVE: Evaluate the effect of pediatric and household
upper respiratory illness/common cold (URI) on employee func-
tion. METHODS: The CHIEF Study is a prospective cohort
study of 2295 United States employees with children among
three large Fortune 500 companies. Prospective monthly survey
responses are collected during the 2007–2008 inﬂuenza season
and linked to an administrative health care claims database. The
survey component asks employees about the effect of both per-
sonal and household member (HHM) illnesses/injuries and URI
on their absenteeism and presenteeism. The administrative claims
database component includes information about health care uti-
lization and expenditures. RESULTS: Initial monthly results indi-
cate that employees with URI (n = 680) reported more days of
absenteeism (0.53 vs. 0.44, respectively; p = 0.2453) and more
hours of presenteeism (0.88 hours vs. 0.38 hours, respectively;
p < 0.0001) than employees without URI (n = 1536). Employees
with at least one HHM experiencing URI reported missing more
days of work (0.17 vs. 0.06, respectively; p = 0.0016) and more
hours of presenteeism (0.43 and 0.14, respectively; p < 0.0001)
than employees reporting otherwise. Among employees reporting
URI, symptoms lasted 4.77 days on average—about half of
which were “most severe” (2.31 days). Employees also reported
that it took 6.20 days to “get back to normal” following
symptom onset. Employees reporting URI and any productivity
loss missed 1.36 days of work and experienced 2.79 hours of
presenteeism because of their symptoms. Productivity was also
negatively affected for employees with at least one HHM expe-
riencing URI—employees reported missing 1.25 days of work
and having 0.56 hours of presenteeism as a result of HHM
symptoms. CONCLUSION: Employees are signiﬁcantly less
productive—in terms of both absenteeism and presenteeism—
when they have URI symptoms. Furthermore, employee produc-
tivity is also signiﬁcantly impacted when a HHM reports URI
symptoms.
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OBJECTIVE: Maraviroc (MVC) is a CCR5 co-receptor antago-
nist indicated for combination antiretroviral treatment of adults
infected with only CCR5-tropic HIV-1 detectable, who have
evidence of viral replication and HIV-1 strains resistant to mul-
tiple antiretroviral agents. The cost-effectiveness of a strategy of
testing and treating with optimized background therapy (OBT),
MVC according to tropism test results, compared to treating
with OBT alone, was modeled from a US payers’ perspective
using 48-week MOTIVATE-1 and -2 trial endpoints.
METHODS: The MOTIVATE screening cohort (mean age:
45 years, male: 86%, mean baseline CD4: 184 cells/mL, mean
baseline HIV-1 RNA: 4.72 log10 copies/mL, CCR5-monotropic:
51%, history of opportunistic infections: 67%) was microsimu-
lated using the previously reported ARAMIS model. To achieve
convergence, the cohort was sampled 200,000 times with
replacement. MVC cost $29/day, tropism testing cost $1960,
and care costs were taken from HIV Research Network data.
Utilities were based on a published US survey. RESULTS: In the
MOTIVATE trials, 56.1% of patients receiving MVC + OBT
and 22.5% receiving OBT alone were virologically suppressed
to <400 copies/mL at 48 weeks. Projecting observed virologic
failure rates linearly, ARAMIS predicted life expectancy of 94.5
and 88.9 months for the OBT MVC and OBT strategies,
respectively. Mean QALYs and lifetime costs per patient were
5.03 and $236,900 for OBT MVC and 4.75 and $220,400
for OBT, for an incremental cost-effectiveness ratio (ICER) of
$60,100 per QALY gained ($55,000–$62,600 over 95% CI for
MVC + OBT suppression). Varying the proportion of CCR5-
monotropic individuals from 30%–80% gave ICERs from
$65,500–$56,400. For patients with HIV susceptible to 2
drugs, life expectancy for OBT MVC and OBT alone was
92.5 and 85.5 months respectively, giving an ICER of $55,400.
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CONCLUSION: The ICER for the maraviroc strategy is com-
parable to values reported for use of antiretrovirals in similar
populations, and was most favorable for individuals with few
active treatment options.
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OBJECTIVE: Nosocomial pneumonia (NP), the second most
common hospital-acquired infection in the US, is associated
with excess morbidity, mortality, hospital days and health care
costs. The objective of this study was to compare treatment
costs and cost-effectiveness of doripenem (currently under FDA
review for NP indication) to two common NP treatments.
METHODS: Outcomes for a population of hospitalized
patients with NP, including a subset of ventilator-associated
pneumonia (VAP) patients were modeled. Patients were
assumed to be treated with doripenem, imipenem or
piperacillin/tazobactam as ﬁrst-line therapy for NP. Clinical
cure and utilization data, including receipt of concomitant
medications (vancomycin/amikacin), days on mechanical venti-
lation (MV), ICU days, and LOS in hospital, were estimated
by combining data from two randomized, multicenter, non-
inferiority clinical trials of doripenem. Wholesale acquisition
costs were used for study drug; costs of MV, ICU and ward
days were estimated from published literature. The primary
outcomes were total costs and incremental cost per clinical
cure. Robustness of the baseline cost-effectiveness analysis was
evaluated using one-way and probabilistic sensitivity analyses
(PSA). RESULTS: In base-case analyses, initial treatment with
doripenem was least costly at $42,041/treated patient, followed
by piperacillin/tazobactam ($43,743), and imipenem ($44,834).
Doripenem dominated piperacillin/tazobactam by being less
costly with a higher probability of clinical cure (72.3% vs.
67.8%). Imipenem had a clinical cure rate of 72.6%, but at an
additional cost of $992,200/cure. Results among the subset of
VAP patients were similar. One-way sensitivity analyses show
the model to be most sensitive to changes in the probability of
cure with each therapy. Probabilistic sensitivity analysis results
indicate that doripenem is cost saving versus imipenem in
77.1% and versus piperacillin/tazobactam in 70.6% of 1,000
iterations. CONCLUSION: First-line therapy with doripenem
yields lower costs and similar efﬁcacy compared to common
NP treatments. Doripenem is a cost-effective treatment for NP
versus imipenem and piperacillin/tazobactam.
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OBJECTIVE: To assess differences in serial mean utility scores,
from Health Utilities Index (HUI) Mark 3 (HUI3) measurements
for patients undergoing treatment for acute lymphoblastic leuke-
mia (ALL) in childhood. These scores will be used for identifying
determinants of health. METHODS: Patients were aged 5 years
or older at time of health-related quality of life (HRQL) survey
and enrolled in the Dana Farber Cancer Institute 95–001 clinical
trial. Parents-of-patients completed self-administered HUI ques-
tionnaires during the four major phases of treatment: induction
of remission (t1); CNS prophylaxis (t2); intensiﬁcation (t3); and
maintenance (t4). HRQL scores are on a scale where 0.00 equals
dead and 1.00 equals perfect health. Signiﬁcant differences
between treatment phases, for mean HRQL and single-attribute
utility scores, were assessed using 1-way ANOVA and paired
t-test. Magnitude of change in mean HRQL scores between
treatment phases was assessed by effect size. Differences in mean
HRQL scores of >0.03 are clinically important. RESULTS: A
total of 375 patients were surveyed (55.2% males). Patients with
complete sets of parental measurements at all treatment phases
were included in this analysis (n = 86). Mean HRQL score
at t1 = 0.68 (SD = 0.306), t2 = 0.74 (SD = 0.245), t3 = 0.77
(SD = 0.267), and t4 = 0.88 (SD = 0.204) (p < 0.001). There was
substantial inter-patient variability in HRQL scores within treat-
ment phases. The effect sizes were 0.200 for t2-t1, 0.120 for t3-t2
and 0.395 for t4-t3. Mean HRQL change scores were 0.06 for t1
to t2 (p = 0.085), 0.03 for t2 to t3 (p = 0.416), and 0.10 for t3 to
t4 (p = 0.001). For single-attribute scores signiﬁcant differences
between treatment phases were observed for ambulation
(p < 0.001), emotion (p < 0.001), pain (p < 0.001). CONCLU-
SION: Mean HRQL, ambulation, emotion and pain scores gen-
erally improved over time. The large inter-patient variability may
reﬂect, in part, the considerable heterogeneity of treatment-
related side effects among patients. Further analyses will explore
whether demographic or diagnostic risk factors contribute to this
variability.
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VALIDATION OFTHE PATIENT HEALTH QUESTIONNAIRE IN
BRFSS—APPLICATION OF CROSS-VALIDATION METHOD
Yeh Y
Mapi Values, Boston, MA, USA
OBJECTIVE: Research has shown that the individuals with
diabetes have a higher chance of being depressed compared to
those without diabetes. To provide effective interventions for
diabetes with depression, practitioners need a reliable and valid
instrument to examine patients’ levels of depression. The
purpose of the study was to evaluate the psychometric proper-
ties of the Patient Health Questionnaire (PHQ) in 2006 Behav-
ioral Risk Factor Surveillance System (BRFSS). METHODS:
The BRFSS is an on-going telephone health survey system,
recording U.S. adults’ health and risk behaviors yearly. The
PHQ measures the depressive symptom that subjects have had
over the last two weeks. In the current investigation, only
Washington residents who were under diabetic treatment(s)
and completed the questionnaire were included in the analyses.
Of 750 subjects in the analyses, 338 (45.07%) were male and
412 (54.93%) were female. The average age was 63.18 years
(SD = 12.53). The split-half, cross-validation method was
applied to assess the psychometric properties of the PHQ.
RESULTS: Exploratory factor analysis was ﬁrst conducted to
determine the measurement structure with the ﬁrst half of the
sample on the ﬁrst step. A one-component solution was
obtained. All items loaded heavily on the target component.
Cronbach coefﬁcient Alpha was 0.82, suggesting good internal
consistency. The second step involved an examination of the
cross-validation of the measurement structures from ﬁrst step
with the second half of the sample using conﬁrmatory factor
analysis procedures. The one-factor model ﬁtted the data well,
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